MARLBOROUGH, Mass.--(BUSINESS WIRE)--CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the first series of patients treated ...
CardioFocus, Inc., a medical device company dedicated to advancing pulsed field ablation (PFA) treatment for cardiac arrhythmias, announced major advancements across its PFA portfolio. OptiShot(TM) -- ...
MARLBOROUGH, Mass., November 11, 2025--(BUSINESS WIRE)--CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced a series of major ...
CardioFocus has treated the first patients in an investigational trial of OptiShot, its pulsed field ablation (PFA) system for treating paroxysmal atrial fibrillation (AF). The patients in the ...
CardioFocus, Inc., a medical device company dedicated to advancing pulsed field ablation (PFA) treatment for cardiac arrhythmias, announced major advancements across its PFA portfolio. OptiShot Unique ...
OptiShot ultra-compliant balloon enables tissue contact and precise anatomic delivery of pulsed energy for treatment of atrial fibrillation in first European patients MARLBOROUGH, Mass.--(BUSINESS ...
OptiShot ultra-compliant balloon enables tissue contact and precise anatomic delivery of pulsed energy for treatment of atrial fibrillation in first European patients CardioFocus, Inc., a medical ...
Running all CardioFocus clinical projects and can support focal, large area focal, regional, and single shot catheter systems for current and future PFA requirements Demonstrated compatibility across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results